CLINICAL STUDIES
LABORATORY AND EXPERIMENTAL STUDIES
Comparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The drugs were administered once in 48 hours after inoculation of ovarian cancer in maximum tolerated doses (MTD). Normothermic intraperitoneal chemoperfusion (IPEC) and hyperthermic intraperitoneal chemoperfusion (HIPEC) were performed with cisplatin or dioxadet at doses that were 5−20 times higher than those for their standard intraperitoneal administration. Antitumor effects of the drugs were estimated in increase of median survival time (MST). In case of IPEC and HIPEC cisplatin increased the MST by 317 % and 183 % (р<0.05) respectively, when dioxadet increased the MST by 244 % and 444 % (р<0.05) respectively compared to the control group of animals that didn’t receive any treatment. HIPEC with dioxadet is the most effective regimen in experimental treatment of advanced ovarian cancer.
ONCOLOGY PRACTICE
REVIEWS
In the last decade, molecularly-targeted therapy is the most intensively developing treatment modalities in oncology. The main targets for this therapy are many elements of apoptosis signaling pathways and cell cycle regulation, the damage of which is associated with a malignant growth. One of the available molecular targets is the epidermal growth factor receptor (EGFR), which activation occurs in lung cancer, colorectal cancer, squamous cell carcinoma of the head and neck , breast cancer, melanomas, etc. To block oncogenic EGFR signaling, target drug as small molecule tyrosine kinase inhibitors, peptide associated cytotoxins and antiEGFR monoclonal antibodies were created. However, there are a number of studies (FLEX, SATURN, INTEREST, IPASS), where the expected and observed clinical cure rates of target drugs are not the same, including primary goal - increasing time to tumor progression. As the cause of inconsistency of treatment results may be lack the selection of patients with the additional molecular damages (mutations or genetic polymorphisms), providing the sensitivity and /or resistance to therapeutic agent. The most important reason for discrepancy between the real and the expected treatment effect of target drugs is the phenomenon of intratumoral heterogeneity, that is manifested as coexist of cells with different biological properties, due to genetic, epigenetic, phenotypic peculiarities of tumor clones within the tumor. Search for new driver targets and the creation of drugs directed against them, development of multitarget approach are perspective to improve the effectiveness of targeted therapy. In addition, it is important to use molecular testing to monitor the treatment efficacy, because therapy can drive the tumor clonal evolution, leading to the emergence of resistant cell clones.
CASE REPORTS
CHRONICLE. INFORMATION
ISSN 2312-3168 (Online)